PlaySide Studios (ASX:PLY) announces that MOUSE: P.I. For Hire surpasses one million units sold across all platforms in less than three months since its global digital launch, generating an estimated US$28.7 million in gross platform sales.

🎮 One million sales: MOUSE: P.I. For Hire reaches more than one million units sold across PC and console platforms, with consoles accounting for around 50% of total unit sales.

💰 Strong commercial performance: The game generates estimated gross platform sales of US$28.7 million (A$41.4 million), with approximately US$17.6 million (A$25.4 million) in net revenue received by PlaySide Studios before Fumi Games` royalties.

🚀 Growth continues: Physical editions are now rolling out globally, while the development of the game`s first paid downloadable content (DLC) aims to attract new players and re-engage the existing community.

"We have been really pleased to see MOUSE: P.I. For Hire sell over one million copies in less than three months since its global digital launch, and the recent Steam Summer Sale provided the catalyst for the title to achieve this milestone.” – PlaySide Studios CEO Benn Skender

Have you heard about the company investing US$100 billion into the US? TSMC stands for Taiwan Semiconductor Manufacturing Company (NYSE:TSM) and it’s one of the world`s largest non-U.S. companies by market capitalisation, valued at almost US$60 trillion.

TSMC is investing another US$100 billion dollars in America for two reasons. The plan follows a major trade and investment deal between the US and Taiwan. In TSMC’s own words, to meet “strong multi-year demand” from its big American tech customers, who can`t get enough of the company`s chips. The money will be used to create new semiconductor plants in Arizona, bringing TSMC`s total US commitment up to US$265 billion.

If you`ve got a super fund, you almost certainly own a slice of TSMC and the AI boom your investments are riding on runs through this one company`s factories.

#AI #wallstreet #tech #stocks #money

Sky Metals (ASX:SKY) has significantly strengthened the investment case for its Tallebung Project in New South Wales after delivering a major Mineral Resource upgrade that exceeded its previous Exploration Target. Ahead of presenting at Noosa Mining, Sky Metals Managing Director & CEO Oliver Davies joins The Stock Network`s Lel Smits to discuss why Tallebung is rapidly emerging as one of Australia`s most compelling critical minerals development stories.

⚒️ A bigger project than expected
🪓 From exploration success to development

Lux Copper Corp. has listed on the ASX with the ticker code of LUX. It is a mining explorer that wholly owns the Baird and Ambler Projects located in the Northwest Arctic Borough, within the US state of Alaska. Both these projects are positioned in the Ambler Mining District, which hosts multiple world-class deposits and producing operations. Lux Copper’s initial focus post listing will be undertaking a maiden drilling program at the Baird Project, where historical drilling has returned high-grade copper and zinc assays, and conducting initial reconnaissance fieldwork at the Ambler Project.

Media: The Stock Network, @lelsmits

Cyclopharm (ASX:CYC) secures an agreement with University Hospitals (UH) in Cleveland, Ohio, for the immediate installation of its Technegas® system across 11 clinical locations, expanding the Company`s presence in the US healthcare market.

🏥 11-site rollout: UH will install Technegas® across all 11 clinical locations over the coming weeks, with site preparation already completed to enable immediate deployment.
🇺🇸 US expansion: The agreement strengthens Cyclopharm`s footprint in northern Ohio and adds another leading US academic health system to its growing network of reference sites.
📈 Recurring revenue: Each installation is expected to generate ongoing revenue through per-patient ventilation imaging procedures, as well as consumables and service income as procedure volumes increase.

"What makes this agreement particularly significant is its immediacy. Rather than a staged rollout over time, UH has elected to install Technegas® system-wide, at 11 locations, over the next few weeks. This deepens our recurring revenue base and reflects the confidence UH has placed in Technegas® at enterprise scale.” – Cyclopharm Managing Director and CEO James McBrayer

What happens when Australia`s biggest mining company starts running low on its most profitable metal? BHP`s latest operational review has just shown that while copper output hit the top of its target range, BHP expects copper production to fall about 12% in the year ahead, mainly due to declining ore grades at its mine in Chile.

Copper is now more important than ever because it is used in EVs, data centres and the energy transition. As a result it also accounts for around half of BHP`s profits, highlighting the reliance on a metal that`s becoming increasingly difficult to mine.

#mining #copper #stocks #money #finance

Oceana Metals (ASX:OCN) is preparing to begin a major 20,000m drilling program at its Serra Negra Rare Earths Project in Brazil, alongside an extensive re-assaying program of historic drill core. The work is designed to determine the size, continuity and potential scale of the rare earths mineralisation ahead of an initial resource estimate planned for 2026. Ahead of presenting at Noosa Mining, Oceana Metals Chair Russell Curtin joins The Stock Network`s Lel Smits to discuss why Serra Negra could emerge as a significant new rare earths discovery.

🇧🇷 Drilling campaign and exploration upside in Brazil
🪓 Resource growth and upcoming catalysts

Neurotech International (ASX:NTI) receives US FDA clearance for its Investigational New Drug (IND) application for NTI164, opening the pathway for US clinical development and supporting the Company`s global registration strategy.

🇺🇸 FDA milestone: The US FDA clears Neurotech International’s IND application for its NTI164, allowing the Company to commence its proposed US clinical development program for this oral cannabinoid drug therapy.
🧪 Global strategy: The planned US study is designed to complement the Australian Phase 3 "Beyond Harmony" trial, supporting future global regulatory submissions.
🌍 Commercial pathway: The milestone strengthens Neurotech International’s global commercialisation strategy and supports ongoing discussions with potential strategic partners.

"Together with our ongoing Australian Phase 3 trial, the data generated under the FDA-cleared IND is expected to create an integrated clinical and regulatory evidence package for NTI164, supporting the Company`s global development, registration and commercialisation strategy." – Neurotech International CEO and Managing Director Anthony Filippis